OraSure Technologies Receives FDA's Emergency Use Authorization For Its OraQuick Ebola 2.0 Rapid Antigen Test
OraSure Technologies, Inc. (NASDAQ:OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that it has received Emergency Use Authorization (EUA) from the
OraSure got permission from the FDA to sell a new fast test that can spot Ebola. This shows the company can make products the government trusts, which might help people feel more confident about what they do.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.